Vascular endothelial growth factor suppresses dendritic cells function of human prostate cancer

被引:19
作者
Bai, Wen-kun [1 ]
Zhang, Wei [1 ]
Hu, Bing [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai Inst Ultrasound Med, Dept Ultrasound Med, Yishan Rd 600, Shanghai 200233, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2018年 / 11卷
基金
中国国家自然科学基金;
关键词
prostate cancer; vascular endothelial growth factor; dendritic cell; immunology; T cell; MICROVESSEL DENSITY; IMMUNOTHERAPY; EXPRESSION; PARAMETERS; PROVENGE; RISK; VEGF;
D O I
10.2147/OTT.S161302
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Purpose: Prostate cancer (PCa) patients often have dendritic cell (DC) function defects, but the mechanism is not clear. The aim of this study was to detect the effect of vascular endothelial growth factor (VEGF) in mature DCs. Patients and methods: In this study, we chose 30 PCa patients, 10 prostatic intraepithelial neoplasia (PIN) patients and 30 benign prostatic hyperplasia (BPH) patients, and compared the composition of peripheral blood T cells, the composition and function of local dendritic cells in prostate tissue, and the density of local VEGF. Results: The results showed that the numbers of total DCs, mature and functional DCs, and CD4(+) T cells were inhibited in PCa, and the inhibitory effect was enhanced with increased malignancy. In addition, the infiltration density of VEGF-positive cells was increased in PCa, and this increase was associated with an increased malignant degree of PCa. The inhibition of tumor immunity in patients with PCa is achieved by inhibiting the function of dendritic cells. Conclusion: VEGF plays an important role in the inhibition of the maturation and function of dendritic cells, and this inhibition is gradually increased with an increasing malignant degree of PCa.
引用
收藏
页码:1267 / 1274
页数:8
相关论文
共 35 条
  • [1] Aalamian M, 2001, PROSTATE, V46, P68
  • [2] Dendritic cell and macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer
    Bauer, Kathrin
    Michel, Sara
    Reuschenbach, Miriam
    Nelius, Nina
    Doeberitz, Magnus von Knebel
    Kloor, Matthias
    [J]. FAMILIAL CANCER, 2011, 10 (03) : 557 - 565
  • [3] Cintolo JA, 2012, FUTURE ONCOL, V8, P1273, DOI [10.2217/FON.12.125, 10.2217/fon.12.125]
  • [4] Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
    Curiel, TJ
    Wei, S
    Dong, HD
    Alvarez, X
    Cheng, P
    Mottram, P
    Krzysiek, R
    Knutson, KL
    Daniel, B
    Zimmermann, MC
    David, O
    Burow, M
    Gordon, A
    Dhurandhar, N
    Myers, L
    Berggren, R
    Hemminki, A
    Alvarez, RD
    Emilie, D
    Curiel, DT
    Chen, LP
    Zou, WP
    [J]. NATURE MEDICINE, 2003, 9 (05) : 562 - 567
  • [5] Datta Jashodeep, 2014, Yale Journal of Biology and Medicine, V87, P491
  • [6] Prostate cancer as a model for tumour immunotherapy
    Drake, Charles G.
    [J]. NATURE REVIEWS IMMUNOLOGY, 2010, 10 (08) : 580 - 593
  • [7] Duque José Luis Ferreira, 2006, Clinics, V61, P401
  • [8] Human cancers converge at the HIF-2α oncogenic axis
    Franovic, Aleksandra
    Holterman, Chet E.
    Payette, Josianne
    Lee, Stephen
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (50) : 21306 - 21311
  • [9] Natural adjuvants: Endogenous activators of dendritic cells
    Gallucci, S
    Lolkema, M
    Matzinger, P
    [J]. NATURE MEDICINE, 1999, 5 (11) : 1249 - 1255
  • [10] EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent-Update 2013
    Heidenreich, Axel
    Bastian, Patrick J.
    Bellmunt, Joaquim
    Bolla, Michel
    Joniau, Steven
    van der Kwast, Theodor
    Mason, Malcolm
    Matveev, Vsevolod
    Wiegel, Thomas
    Zattoni, F.
    Mottet, Nicolas
    [J]. EUROPEAN UROLOGY, 2014, 65 (01) : 124 - 137